Author:

About 10 percent of new drugs complete the first phase of a clinical trial but patient participation drops by 30

Clinical trials are often unsuccessful or incomplete due to the huge costs and other issues associated with recruitment and keeping

Prescreening potential subjects in oncology clinical trials is one of the most significant limiting factors in identifying eligible participants which

The goals of drug development process involves supporting all stakeholders in improving patient care, addressing challenges associated with financial sustainability